SB1795

Creates provisions relating to biomarker testing

Introduced·2/26/26
Introduced Text

Missouri SB1795 mandates coverage for biomarker testing for diagnosis, treatment, and management of diseases.

Missouri SB1795 amends the MO HealthNet program to cover biomarker testing for diagnosis, treatment, and management of diseases when it provides clinical utility. This coverage applies to biomarker testing for participants in the MO HealthNet program and for individuals with health insurance contracts. The bill defines biomarker and biomarker testing, and it specifies that coverage does not extend to screening purposes. The Department of Commerce and Insurance is tasked with adopting necessary rules to implement these provisions.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Families, Seniors and Health Committee
Next
Committee decision

Sponsors

D
1
0
Democratic CaucusRepublican Caucus

History

May 7

Senate

Second Read and Referred S Families, Seniors and Health Committee

Feb 26

Senate

S First Read